ABL Bio Inc. (Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com
View Top Employees from ABL Bio Inc.Website | http://www.ablbio.com/en |
Revenue | $2 million |
Employees | 52 (44 on RocketReach) |
Founded | 2016 |
Address | 16 Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, KR |
Phone | +82 31-8018-9800 |
Technologies |
JavaScript,
HTML,
Google Analytics
+12 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Business Services General, Business Services, Science and Engineering, Drug Discovery, Health Care, Medical |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 541713 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies |
Looking for a particular ABL Bio Inc. employee's phone or email?
The ABL Bio Inc. annual revenue was $2 million in 2024.
44 people are employed at ABL Bio Inc..
ABL Bio Inc. is based in Seongnam-si, Gyeonggi-do.
The NAICS codes for ABL Bio Inc. are [541, 5417, 541713, 54, 54171].
The SIC codes for ABL Bio Inc. are [87, 873].